Histologically it is nearly impossible to distinguish the dedifferentiated component of dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone when the low-grade cartilaginous component is absent. Previous studies have revealed that isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations are present in a significant number of cartilaginous tumors including the majority of conventional chondrosarcoma and dedifferentiated chondrosarcomas. These mutations have not been studied in undifferentiated pleomorphic sarcomas of bone. We sought to investigate whether an IDH1 or IDH2 mutation signature could be used as a clinically diagnostic marker for the distinction of dedifferentiated component of chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. Sixty-eight bone tumor cases, including 31 conventional chondrosarcomas, 23 dedifferentiated chondrosarcomas, and 14 undifferentiated pleomorphic sarcomas of bone, were collected for IDH1/2 mutation analysis either using the Qiagen IDH1/2 RGQ PCR Kit or using whole exome sequencing. IDH1/2 mutations were detected in 87% (20/23) of dedifferentiated chondrosarcomas and 30% (6/20) of conventional chondrosarcomas. No mutations were detected in the IDH1/2 codon 132 or codon 172 among 14 UPS of bone. Identification of IDH1 or IDH2 mutations supports the diagnosis of dedifferentiated chondrosarcoma rather than undifferentiated pleomorphic sarcoma of bone while also providing some insight into the pathogenesis of these two lesions.
Introduction
Chondrosarcoma, a malignant cartilaginous tumor, is the second most common primary malignancy of bone after osteosarcoma, often arising from the pelvis, femur, or humerus.
Tumors are classified as conventional chondrosarcoma when the histology resembles nonneoplastic cartilage, as opposed to dedifferentiated chondrosarcoma containing areas of high grade sarcoma. The most common morphological pattern of the dedifferentiated component is undifferentiated pleomorphic sarcoma (UPS), so-called malignant fibrous histiocytoma (MFH).
Diagnosis of dedifferentiated chondrosarcoma relies on identifying both the well-differentiated cartilaginous and dedifferentiated components (1) . UPS of bone is commonly located in the lower extremities, particularly the femur followed by tibia and pelvis. Morphologically, tumors are composed of atypical spindled and pleomorphic cells which may be arranged in a storiform, fascicular or haphazard pattern with marked nuclear pleomorphism, mitoses, and necrosis (2, 3) .
Importantly, these tumors lack chondroid and osteoid matrix deposition.
Although dedifferentiated chondrosarcoma and UPS of bone may share clinical presentations, including arising in similar anatomical locations, dedifferentiated chondrosarcoma is extremely aggressive with a dismal prognosis. Most patients with dedifferentiated chondrosarcoma die within 2 years of initial presentation. The 5-year survival rate is 19% based on a large study of 52 cases but ranges from 7.1 to 24% in studies throughout the literature (4, 5) . With the lack of convincing evidence of the benefit of chemotherapy, complete surgical excision is the initial recommended treatment. UPS of bone is also aggressive. However, neoadjuvant or adjuvant chemotherapy is beneficial with the improved 5-year survival rate up to 59% (median survival time 63 months) (3, 6) . In fact, neoadjuvant chemotherapy using an osteosarcoma treatment allele. These mutations lead to a reduced capacity to convert ICT to α-KG and a gain of function (19) . The pathogenesis by D-2-hydroxygluturate has been under extensive study (17, (19) (20) (21) .
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The fact that IDH1/2 mutations are present in dedifferentiated chondrosarcoma and have not been studied in UPS of bone prompted us to evaluate whether an IDH1 and IDH2 mutation signature could be used as a molecular diagnostic marker to distinguish these two lesions, as well as give insight into the pathogenesis of these two lesions and provide useful information for clinical management.
MATERIALS AND METHODS

Ethics Statement
This study was approved by the Institutional Review Board of Indiana University, Mayo Clinic and University of Alabama at Birmingham. Resected specimens were submitted for routine histological diagnoses and the remaining tissues were used for research. There was no compromise of the patient's privacy.
Collection of Tumor Specimens
After searching pathology information system databases, cases of conventional chondrosarcoma and dedifferentiated chondrosarcoma were collected from Indiana University, Mayo Clinic, and 
DNA Extraction
DNA extraction from formalin-fixed, paraffin-embedded tissue was performed using a QIAamp of IDH1/2 genes, respectively.
Immunohistochemical Staining
Immunohistochemical staining was performed according to a previously published protocol (25) .
Only two changes were made to the protocol: Antigen retrieval was performed using Tris-EDTA buffer, pH 9.0 in a PT module (Dako) for 15 minutes and a mouse anti-human IDH1 R132H monoclonal antibody (Catalog number DIA H09, Dianova, Hamburg, Germany) was used at 1:60 dilution as a primary antibody to detect mutated IDH1 R132H enzyme. Human glioma was 
RESULTS
Clinicopathologic Features
A total of 68 cases were collected for IDH1/2 mutation analysis and included 31 conventional chondrosarcomas, 23 dedifferentiated chondrosarcomas, and 14 UPS of bone. Among the 31 chondrosarcoma cases as shown in Table 1 , the tumor size ranged from 1. (Table 2 ) ranged from 4.2 cm to 26.0 cm (mean, 11.6 cm; median, 9.9 cm). All but one were primary lesions; the exception being a metastatic lesion in the liver. The primary tumors mainly arose from the femur (n=8), humerus (n=6), and pelvis (n=5).
The tumor size of UPS of bone (Table 3) ranged from 3.0 cm to 12.5 cm (mean, 8.3 cm; median,
cm). The primary tumors mainly arose from the femur (n=9) and tibia (n=2).
Cases of conventional chondrosarcoma showed hyaline cartilage neoplasms containing variable numbers of atypical chondrocytes with enlarged, hyperchromatic nuclei (Fig. 1A) . Those classified as dedifferentiated chondrosarcoma were biphasic tumors with areas of low-grade chondrosarcoma juxtaposed to foci containing atypical spindle and epithelioid cells with marked nuclear atypia (Fig. 1B) . Typically, there was an abrupt transition between the cartilaginous and the non-chondrogenic sarcomatous component (Fig. 1C) . UPS of bone revealed atypical spindle
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S Chen et al 10 and epithelioid cells with nuclear pleomorphism, hyperchromatism and readily-identifiable mitoses, lacking any specific line of differentiation by immunohistochemistry (Fig. 1D ).
Mutational Analysis
Among the 31 cases of conventional chondrosarcoma, IDH1/2 mutation analysis was successfully performed in 20 (65%). Of the 20 successful samples, 6 (30%) harbored a somatic mutation in either IDH1 or IDH2 ( Table 1 ). The majority of mutations were detected in the IDH1 gene (n=4) and included R132H (1), R132C (2), and R132 (1) (Table 3 ).
Detection of IDH1 R132H Mutated Enzyme Expression Using Immunostaining
One conventional chondrosarcoma (Table 1 , case 1) and one dedifferentiated chondrosarcoma (Table 2 , case 19) were found to contain single IDH1 R132H mutation. Therefore
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S Chen et al 11 immunostaining was performed to confirm the presence of the mutated IDH1 R132H protein expression in these two cases. Cytoplasmic staining was clearly demonstrated in the atypical chondrocytes of the conventional chondrosarcoma (Fig. 2B ) and the dedifferentiated component the dedifferentiated chondrosarcoma (Fig. 2C ).
DISCUSSION
Dedifferentiated chondrosarcoma is a highly aggressive biphasic mesenchymal tumor consisting of a well-differentiated cartilaginous component admixed with area of high-grade sarcoma. With extensive sampling and careful correlation with radiologic findings, the diagnosis is often straightforward. However, in the advent of core biopsy techniques, the conventional cartilaginous component can be easily missed. Specifically, if the biopsy only shows the high grade sarcomatous component, distinction from UPS of bone is nearly impossible with morphology alone. As treatment protocols and prognosis differ for these two entities, accurate diagnosis is critical.
Our results show that the presence of an IDH1 or IDH2 mutation strongly supports the diagnosis of dedifferentiated chondrosarcoma rather than UPS of bone. While an IDH1/2 mutation was identified in the dedifferentiated component of 87% (20 of 23 cases) of our dedifferentiated chondrosarcomas, no UPS of bone (0 of 14 cases) harbored a detectable aberration in these genes. Therefore, IDH1 and IDH2 mutational analysis seems to be a robust strategy to be used in distinguishing these two lesions. Interestingly, the incidence of IDH1/2 mutations in dedifferentiated chondrosarcoma in our series is slightly higher than what has previously (14, 16) . We also showed concordance of mutation status in both well-differentiated and dedifferentiated components in three cases in which both regions we successfully analyzed. This is consistent with the previous report which demonstrated the same mutation detected in both components (grade I and dedifferentiated) in four cases (14) .
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While the concept of dedifferentiation has long been recognized, these findings provide further evidence to support shared pathogenesis for both components. Furthermore, the absence of IDH1/2 mutations in UPS of bone yields insight into the biological difference between dedifferentiated chondrosarcoma and undifferentiated pleomorphic sarcoma of bone.
Among a total of 11 cases of dedifferentiated chondrosarcoma with IDH1 mutations in this study, 1 case harbored an IDH1 R132H mutation, which was also confirmed by immunostaining using monoclonal antibody. Although the IDH1 R132H mutation occurs in approximately 70%
of WHO grade II and III gliomas (7), it was detected in only 17% of the IDH 1/2 mutations present in cartilaginous tumors in one study (14) and 0% (0/14 positive cases) in another study (15) . While the IDH1 R132H monoclonal antibody appears to be a reliable surrogate for mutation status, the low rate of its prevalence in dedifferentiated chondrosarcoma limits its usefulness in this setting. One potential drawback of performing mutational analysis on bone tumors is that the decalcification procedure involves hydrochloric acid which is known to cause DNA damage through chemical hydrolysis which has been previously discussed by Kerr and colleagues in their analysis of IDH1/2 mutations in chondoblastic osteosarcoma (15) Consequently, tumor sections with significant bone matrix may be subjected to this process, often rendering them unsuitable for these studies. Eleven cases of conventional chondrosarcoma with unsuccessful mutation analysis were exposed to decalcification techniques (Table 1) . Fortunately, the dedifferentiated component of dedifferentiated chondrosarcoma, as well as UPS of bone, often lacks osteoid or bone matrix. In our series, mutation analysis was successful in all 23 cases of dedifferentiated chondrosarcoma and 14 UPS of bone by selecting tissue sections not previously decalcified.
Nonetheless, pathologists should be aware of the limitations of molecular analysis after decalcification procedures. 
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